Detail akcie ADOCIA online

Business Summary: Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Adocia SA revenues decreased 84% to EUR1.5M. Net loss increased 78% to EUR16.6M. Revenues reflect Research and collaborative agreements decrease from EUR9.3M to EUR0K. Higher net loss reflects France segment loss increase from EUR7.4M to EUR15.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.62945 to -EUR0.9261.